Lipella Pharmaceuticals Inc. (LIPO) — SEC Filings
Lipella Pharmaceuticals Inc. (LIPO) — 50 SEC filings. Latest: 10-Q (Nov 14, 2025). Includes 33 8-K, 6 10-Q, 5 SC 13D/A.
View Lipella Pharmaceuticals Inc. on SEC EDGAR
Overview
Lipella Pharmaceuticals Inc. (LIPO) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 14, 2025: Lipella Pharmaceuticals Inc. reported a net loss of $1,254,078 for the three months ended September 30, 2025, a decrease from the $1,444,637 net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $3,888,087, compared to $3,574,592 in the prior year. Total
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 8 bearish, 41 neutral, 1 mixed. The dominant filing sentiment for Lipella Pharmaceuticals Inc. is neutral.
Filing Type Overview
Lipella Pharmaceuticals Inc. (LIPO) has filed 6 10-Q, 33 8-K, 2 10-K, 2 DEF 14A, 5 SC 13D/A, 2 SC 13G/A with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of LIPO's 47 recent filings, 8 were flagged as high-risk, 32 as medium-risk, and 7 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | -$1,254,078 |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $1,855,771 |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Dr. Jonathan Kaufman
- Dr. Jonathan L. Cohen
- Dr. Robert L. Diamond
- Michael B. Chancellor
- David E. Danovitch, Esq.
- Kaufman Jonathan H
- Jonathan H. Kaufman
Industry Context
Lipella Pharmaceuticals operates in the highly competitive and capital-intensive pharmaceutical industry, which is characterized by long development cycles, significant R&D investment, and stringent regulatory oversight. Companies in this sector often face challenges in revenue generation until products gain market approval and traction. The current environment demands continuous innovation and efficient operational management to navigate clinical trials, regulatory hurdles, and market access.
Top Tags
material-agreement (9) · equity-sale (7) · amendment (7) · delisting (6) · financials (6) · 8-K (5) · filing (5) · listing-standards (4) · regulatory-filing (4) · 10-Q (4)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (Q3 2025) | $1,254,078 | Decreased from $1,444,637 in Q3 2024 |
| Net Loss (YTD Sep 2025) | $3,888,087 | Increased from $3,574,592 in YTD Sep 2024 |
| Total Revenues (Q3 2025) | $0 | Significant decrease from $80,380 in Q3 2024 |
| Total Revenues (YTD Sep 2025) | $216,117 | Decreased from $362,691 in YTD Sep 2024 |
| Accumulated Deficit | $19,228,194 | Increased from $15,340,107 at Dec 31, 2024 |
| Cash and Cash Equivalents | $1,855,771 | Decreased from $2,184,863 at Dec 31, 2024 |
| Common Stock Shares Outstanding | 4,620,837 | As of November 13, 2025 |
| Research and Development Expenses (Q3 2025) | $720,973 | Decreased from $1,046,693 in Q3 2024 |
| General and Administrative Expenses (Q3 2025) | $553,299 | Increased from $493,102 in Q3 2024 |
| Net Loss (Q2 2025) | $1.33M | Increased from $0.94M in Q2 2024, indicating widening losses. |
| Net Loss (H1 2025) | $2.63M | Increased from $2.13M in H1 2024, reflecting continued operational losses. |
| Proceeds from Stock Issuance | $3.46M | Key financing activity in H1 2025 to bolster cash position. |
| Research and Development Expense (Q2 2025) | $791,581 | Increased by 19.6% from Q2 2024, indicating higher investment in drug development. |
| General and Administrative Expense (Q2 2025) | $651,721 | Increased by 52.6% from Q2 2024, contributing to higher operating costs. |
| Grant Revenues (Q2 2025) | $86,727 | Decreased from $136,431 in Q2 2024, showing a decline in external funding. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Lipella Pharmaceuticals Inc. (LIPO)?
Lipella Pharmaceuticals Inc. has 50 recent SEC filings from Jan 2024 to Nov 2025, including 33 8-K, 6 10-Q, 5 SC 13D/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of LIPO filings?
Across 50 filings, the sentiment breakdown is: 8 bearish, 41 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Lipella Pharmaceuticals Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Lipella Pharmaceuticals Inc. (LIPO) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Lipella Pharmaceuticals Inc.?
Key financial highlights from Lipella Pharmaceuticals Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for LIPO?
The investment thesis for LIPO includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Lipella Pharmaceuticals Inc.?
Key executives identified across Lipella Pharmaceuticals Inc.'s filings include Dr. Jonathan Kaufman, Dr. Jonathan L. Cohen, Dr. Robert L. Diamond, Michael B. Chancellor, David E. Danovitch, Esq. and 2 others.
What are the main risk factors for Lipella Pharmaceuticals Inc. stock?
Of LIPO's 47 assessed filings, 8 were flagged high-risk, 32 medium-risk, and 7 low-risk.
What are recent predictions and forward guidance from Lipella Pharmaceuticals Inc.?
Forward guidance and predictions for Lipella Pharmaceuticals Inc. are extracted from SEC filings as they are enriched.